The treatment of mycosis fungoides. Adjuvant topical mechlorethamine after electron beam therapy Academic Article Article uri icon


MeSH Major

  • Hematopoietic Stem Cell Transplantation
  • Lung Diseases, Fungal
  • Respiratory Insufficiency


  • The feasibility of employing adjuvant topical mechlorethamine after electron beam therapy in the treatment of patients with mycosis fungoides is demonstrated. Patients treated with a planned adjuvant topical mechlorethamine schedule had a median disease-free interval of 25 months compared to 17 months for the group treated with electron beam therapy alone. Projected relapse-free survivals are slightly better in the adjuvant group--37% versus 29%. Patients receiving adjuvant topical mechlorethamine after the electron beam were observed to have a low incidence of contact allergy to the medication. The topical medication can be continued if a contact allergy develops by using a planned desensitization program. We currently treat all mycosis fungoides patients with electron beam therapy, randomizing half to receive adjuvant topical mechlorethamine.

publication date

  • January 1977



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197712)40:6<2851::AID-CNCR2820400615>3.0.CO;2-X

PubMed ID

  • 412580

Additional Document Info

start page

  • 2851

end page

  • 3


  • 40


  • 6